Experimental conditions that enhance potency of an antibacterial oligo-acyl-lysyl.
Oligo-acyl-lysyls (OAKs) are synthetic mimics of host defense peptides known to exert antibacterial activity both in cultures and in animal models of disease. Here, we investigated how environmental conditions (temperature, pH, and ionic strength) affect the antibacterial properties of an octamer derivative, C(12)K-7alpha(8). Data obtained with representative bacteria, including the Gram-negative bacterium Escherichia coli and the Gram-positive bacteria Listeria monocytogenes and Staphylococcus aureus, showed that OAK's potency was proportionally affected by pH changes and subsided essentially throughout a wide range of salt concentrations and temperature values, whereas antistaphyloccocal activity was relatively more vulnerable. It was rather the mode of action that was most susceptible to the environmental changes. Thus, OAK's bactericidal effect was limited to a growth-inhibitory effect under acidic pH, low temperatures, or high salt concentrations, whereas basic pH or high temperatures have enhanced the bactericidal kinetics. Properties of binding to model phospholipid membranes provided evidence that correlated the differential modes of action with variable binding affinities. Interestingly, combination of the optimal incubation conditions resulted in a remarkable increase in potency, as expressed by a 16- to 32-fold reduction in the MIC value and by much faster bactericidal rates (>99% death induced within minutes versus hours) compared with the standard incubation conditions. Collectively, the data suggest that OAKs might be useful in developing design strategies for robust antimicrobial peptides that are able to affect a pathogen's viability under a large spectrum of incubation conditions.
Goldfeder
Yair
Y
Laboratory of Host Defense Peptides Investigation (HDPI), Department of Biotechnology & Food Engineering, Technion-Israel Institute of Technology, Haifa, Israel.
Zaknoon
Fadia
F
Mor
Amram
A
D000900:Anti-Bacterial Agents / Q000737:chemistry* / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D004926:Escherichia coli / Q000187:drug effects; D006863:Hydrogen-Ion Concentration; D008089:Listeria monocytogenes / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D018716:Molecular Mimicry; D009842:Oligopeptides / Q000737:chemistry* / Q000494:pharmacology*; D009994:Osmolar Concentration; D013211:Staphylococcus aureus / Q000187:drug effects; D013329:Structure-Activity Relationship; D013696:Temperature
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D009842:Oligopeptides
Peptides. 2002 Dec;23(12):2071-83
12535685
Antimicrob Agents Chemother. 2009 Oct;53(10):4231-9
19620333
Peptides. 2003 Nov;24(11):1815-21
15019214
Biopolymers. 2002;66(4):236-48
12491537
Antimicrob Agents Chemother. 2008 Dec;52(12):4308-14
18838600
Chem Biol. 2006 Apr;13(4):427-35
16632255
FASEB J. 2009 Dec;23(12):4299-307
19706728
Int J Pept Protein Res. 1990 Mar;35(3):161-214
2191922
Nat Rev Microbiol. 2005 Mar;3(3):238-50
15703760
J Am Chem Soc. 2008 Dec 10;130(49):16622-32
19049458
Pharmacol Rev. 2003 Mar;55(1):27-55
12615953
Nature. 2002 Jan 24;415(6870):389-95
11807545
Int J Food Microbiol. 2007 Jan 1;113(1):1-15
17010463
Microbiol Mol Biol Rev. 2007 Jun;71(2):377-97
17554049
J Am Chem Soc. 2009 Jul 22;131(28):9735-45
19601684
Chem Biol. 2009 Dec 24;16(12):1250-8
20064435
Infect Immun. 1993 Jul;61(7):2978-84
8514403
Biochemistry. 2003 Nov 11;42(44):12866-74
14596600
Clin Infect Dis. 2008 Dec 15;47(12):1537-45
18990064
Int J Food Microbiol. 2002 Feb 5;72(3):225-31
11845821
J Bacteriol. 2004 Sep;186(18):6032-41
15342572
Biochim Biophys Acta. 2009 Aug;1788(8):1582-92
19028449
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2794-9
18287037
Int J Food Microbiol. 2007 Nov 30;120(1-2):51-70
17614151
Acc Chem Res. 2008 Oct;41(10):1366-75
18578513
Proc Biol Sci. 2006 Jan 22;273(1583):251-6
16555795
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):6968-73
19359494
Lancet Infect Dis. 2003 Jul;3(7):405-12
12837345
Infect Immun. 1997 Jul;65(7):2898-903
9199465
Mol Microbiol. 1998 Dec;30(5):905-10
9988468
Int J Syst Bacteriol. 1999 Apr;49 Pt 2:653-62
10408878
Nat Rev Microbiol. 2006 Jun;4(6):423-34
16710323
Antimicrob Agents Chemother. 2006 Feb;50(2):490-7
16436701
J Leukoc Biol. 2005 Apr;77(4):466-75
15582982
Chem Biol. 2008 Apr;15(4):354-62
18420142
Nat Biotechnol. 2007 Jun;25(6):657-9
17529972
J Am Chem Soc. 2008 Oct 29;130(43):14346-52
18826221
Appl Environ Microbiol. 1997 Sep;63(9):3451-7
9292996
Biochim Biophys Acta. 2009 Aug;1788(8):1570-81
19046939
Antimicrob Agents Chemother. 2007 May;51(5):1753-9
17307975
Biochim Biophys Acta. 1999 Dec 15;1462(1-2):11-28
10590300
BioDrugs. 2003;17(4):233-40
12899640
J Am Chem Soc. 2007 Dec 19;129(50):15474-6
18034491
FASEB J. 2010 Jun;24(6):1904-13
20124435
Nat Biotechnol. 2006 Dec;24(12):1551-7
17160061
Curr Microbiol. 2008 Dec;57(6):552-7
18810542
FEBS J. 2009 Nov;276(22):6474-82
19817857
Appl Environ Microbiol. 1999 Feb;65(2):618-25
9925591
J Food Prot. 1995 Apr;58(4):381-388
31137349
Curr Eye Res. 2005 Jul;30(7):505-15
16020284
FASEB J. 2008 Aug;22(8):2652-61
18385215
Curr Opin Biotechnol. 2008 Dec;19(6):620-7
18996193